• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于药效-药代动力学关联的连归宁心汤治疗心律失常的作用机制及药效物质研究

Study on the mechanisms and Pharmacodynamic substances of Lian-Gui-Ning-Xin-Tang on Arrhythmia Therapy based on Pharmacodynamic-Pharmacokinetic associations.

作者信息

Jiayu Liang, Xiaofeng Li, Jinhong Chen, Fangjun Deng, Boya Fan, Xin Zhen, Zidong Cong, Rui Tao, Lu Yu, Shule Qian, Runying Wang, Wuxun Du

机构信息

Department of TCM, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Hangzhou 310003, China.

Department of Cardiology, The Second Affiliated Hospital of Tianjin University of TCM, Tianjin 300150, China.

出版信息

Heliyon. 2024 Aug 14;10(16):e36104. doi: 10.1016/j.heliyon.2024.e36104. eCollection 2024 Aug 30.

DOI:10.1016/j.heliyon.2024.e36104
PMID:39253118
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11381611/
Abstract

BACKGROUND

The Chinese herbal compound Lian-Gui-Ning-Xin-Tang (LGNXT), composed of 9 herbs, has a significant antiarrhythmic effect. Previous studies have confirmed that preventing intracellular Ca overload and maintaining intracellular Ca homeostasis may be the important antiarrhythmic mechanisms of LGNXT. Recent studies are focused on elucidating the mechanisms and pharmacodynamic substances of LGNXT.

PURPOSE

  1. To investigate the antiarrhythmic mechanisms of LGNXT; 2) to explore the association of pharmacodynamics (PD) and pharmacokinetics (PK) of the potential pharmacodynamic substances in LGNXT to further verify the mechanisms of action.

METHODS

First, pharmacodynamic studies were conducted to determine the effect of LGNXT in arrhythmia at the electrophysiological, molecular, and tissue levels, and the "effect-time" relationship of LGNXT was further proposed. Next, an HPLC-MS/MS method was established to identify the "dose-time" relationship of the 9 potential compounds. Combining the "effect-time" and "dose-time" curves, the active ingredients closely related to the inhibition of inflammation, oxidative stress, and energy metabolism were identified to further verify the mechanisms and pharmacodynamic substances of LGNXT.

RESULTS

Pretreatment with LGNXT could delay the occurrence of arrhythmias and reduce their duration and severity. LGNXT exerted antiarrhythmic effects by inhibiting MDA, LPO, IL-6, and cAMP; restoring Cx43 coupling function; and upregulating SOD, Ca-ATPase, and Na-K-ATPase levels. PK-PD association showed that nobiletin, methylophiopogonanone A, trigonelline, cinnamic acid, liquiritin, dehydropolisic acid, berberine, and puerarin were the main pharmacodynamic substances responsible for inhibiting the inflammatory response in arrhythmia. Methylophiopogonanone A, dehydropalingic acid, nobiletin, trigonelline, berberine, and puerarin in LGNXT exerted antiarrhythmic effects by inhibiting oxidative stress. Dehydropalingic acid, berberine, cinnamic acid, liquiritin, puerarin, trigonelline, methylophiopogonanone A, nobiletin, and tetrahydropalmatine exerted antiarrhythmic effects by inhibiting the energy-metabolism process.

CONCLUSIONS

LGNXT had a positive intervention effect on arrhythmias, especially ventricular tachyarrhythmias, which could inhibit inflammation, oxidative stress, and energy metabolism; positively stabilize the structure, and remodify the function of myocardial cell membranes. Additionally, the PD-PK association study revealed that methylophiopogonanone A, berberine, trigonelline, liquiritin, puerarin, tetrahydropalmatine, nobiletin, dehydropachymic acid, and cinnamic acid directly targeted inflammation, oxidative stress, and energy metabolism, which could be considered the pharmacodynamic substances of LGNXT. Thus, the antiarrhythmic mechanisms of LGNXT were further elucidated.

摘要

背景

由9味中药组成的中药复方连归宁心汤(LGNXT)具有显著的抗心律失常作用。既往研究证实,防止细胞内钙超载和维持细胞内钙稳态可能是LGNXT重要的抗心律失常机制。近期研究聚焦于阐明LGNXT的作用机制和药效物质。

目的

1)研究LGNXT的抗心律失常机制;2)探讨LGNXT中潜在药效物质的药效学(PD)与药代动力学(PK)的相关性,进一步验证其作用机制。

方法

首先进行药效学研究,从电生理、分子和组织水平确定LGNXT对心律失常的作用,并进一步提出LGNXT的“效应-时间”关系。其次,建立高效液相色谱-串联质谱(HPLC-MS/MS)方法,确定9种潜在化合物的“剂量-时间”关系。结合“效应-时间”和“剂量-时间”曲线,确定与抑制炎症、氧化应激和能量代谢密切相关的活性成分,进一步验证LGNXT的作用机制和药效物质。

结果

LGNXT预处理可延迟心律失常的发生,降低其持续时间和严重程度。LGNXT通过抑制丙二醛(MDA)、脂质过氧化物(LPO)、白细胞介素-6(IL-6)和环磷酸腺苷(cAMP)发挥抗心律失常作用;恢复连接蛋白43(Cx43)耦联功能;上调超氧化物歧化酶(SOD)、钙-ATP酶和钠-钾-ATP酶水平。PK-PD相关性分析表明,川陈皮素、麦冬甲基黄烷酮A、胡芦巴碱、肉桂酸、甘草苷、脱水茯苓酸、小檗碱和葛根素是LGNXT中抑制心律失常炎症反应的主要药效物质。LGNXT中的麦冬甲基黄烷酮A、脱水茯苓酸、川陈皮素、胡芦巴碱、小檗碱和葛根素通过抑制氧化应激发挥抗心律失常作用。脱水茯苓酸、小檗碱、肉桂酸、甘草苷、葛根素、胡芦巴碱、麦冬甲基黄烷酮A、川陈皮素和延胡索乙素通过抑制能量代谢过程发挥抗心律失常作用。

结论

LGNXT对心律失常尤其是室性快速性心律失常有积极的干预作用,可抑制炎症、氧化应激和能量代谢;积极稳定心肌细胞膜结构,重塑其功能。此外,PD-PK相关性研究表明,麦冬甲基黄烷酮A、小檗碱、胡芦巴碱、甘草苷、葛根素、延胡索乙素、川陈皮素、脱水茯苓酸和肉桂酸直接作用于炎症、氧化应激和能量代谢,可认为是LGNXT的药效物质。由此进一步阐明了LGNXT的抗心律失常机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/f98cdd52d7c5/mmcfigs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/196c5cf0b3ca/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/0edda7094467/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/43cde2da653f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/fc4aad5e13fd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/91dcd9f86ad9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/4ebe6cc1788a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/ae4337bc117f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/f2183d18ec24/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/a9fa8e50acac/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/7ad01e4cf3ba/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/c60d7c71bd97/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/01bdb7bf81f4/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/56789eabdb40/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/e82f2bbec460/gr13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/f80589b11ff9/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/700eadcc7785/gr15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/c34090de63cc/gr16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/999da40dcb4f/gr17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/28ad865c5eb7/mmcfigs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/163cc9635726/mmcfigs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/e822bb6da0ef/mmcfigs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/4835331882d7/mmcfigs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/30ae1bc47b3c/mmcfigs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/f98cdd52d7c5/mmcfigs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/196c5cf0b3ca/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/0edda7094467/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/43cde2da653f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/fc4aad5e13fd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/91dcd9f86ad9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/4ebe6cc1788a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/ae4337bc117f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/f2183d18ec24/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/a9fa8e50acac/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/7ad01e4cf3ba/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/c60d7c71bd97/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/01bdb7bf81f4/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/56789eabdb40/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/e82f2bbec460/gr13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/f80589b11ff9/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/700eadcc7785/gr15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/c34090de63cc/gr16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/999da40dcb4f/gr17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/28ad865c5eb7/mmcfigs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/163cc9635726/mmcfigs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/e822bb6da0ef/mmcfigs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/4835331882d7/mmcfigs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/30ae1bc47b3c/mmcfigs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6af2/11381611/f98cdd52d7c5/mmcfigs6.jpg

相似文献

1
Study on the mechanisms and Pharmacodynamic substances of Lian-Gui-Ning-Xin-Tang on Arrhythmia Therapy based on Pharmacodynamic-Pharmacokinetic associations.基于药效-药代动力学关联的连归宁心汤治疗心律失常的作用机制及药效物质研究
Heliyon. 2024 Aug 14;10(16):e36104. doi: 10.1016/j.heliyon.2024.e36104. eCollection 2024 Aug 30.
2
Mechanisms of Lian-Gui-Ning-Xin-Tang in the treatment of arrhythmia: Integrated pharmacology and in vivo pharmacological assessment.连归宁心汤治疗心律失常的机制:整合药理学与体内药理学评价
Phytomedicine. 2022 May;99:153989. doi: 10.1016/j.phymed.2022.153989. Epub 2022 Feb 12.
3
Pharmacokinetic-Pharmacodynamic Modeling of the Antioxidant Activity of Quzhou Fructus Aurantii Decoction in a Rat Model of Hyperlipidemia.枳壳汤对高脂血症大鼠模型抗氧化活性的药代动力学-药效学建模
Biomed Pharmacother. 2020 Nov;131:110646. doi: 10.1016/j.biopha.2020.110646. Epub 2020 Sep 14.
4
Investigation of the potential curative effects of Gui-Zhi-Jia-Ge-Gen decoction on wind-cold type of common cold using multidimensional analysis.采用多维分析研究桂枝加葛根汤治疗风寒型普通感冒的潜在疗效。
J Ethnopharmacol. 2022 Nov 15;298:115662. doi: 10.1016/j.jep.2022.115662. Epub 2022 Aug 27.
5
Spectrum-effect relationship analysis based on HPLC-FT-ICR-MS and multivariate statistical analysis to reveal the pharmacodynamic substances of Ling-Gui-Zhu-Gan decoction on Alzheimer's disease.基于 HPLC-FT-ICR-MS 和多元统计分析的谱效关系研究揭示灵龟柱肝汤治疗阿尔茨海默病的药效物质
J Pharm Biomed Anal. 2024 Jan 5;237:115765. doi: 10.1016/j.jpba.2023.115765. Epub 2023 Oct 4.
6
Identifying potential quality markers of Xin-Su-Ning capsules acting on arrhythmia by integrating UHPLC-LTQ-Orbitrap, ADME prediction and network target analysis.通过整合 UHPLC-LTQ-Orbitrap、ADME 预测和网络靶标分析,鉴定心速宁胶囊抗心律失常的潜在质量标志物。
Phytomedicine. 2018 May 15;44:117-128. doi: 10.1016/j.phymed.2018.01.019. Epub 2018 Feb 10.
7
A stepwise integrated multi-system to screen quality markers of Chinese classic prescription Qingzao Jiufei decoction on the treatment of acute lung injury by combining 'network pharmacology-metabolomics-PK/PD modeling'.采用“网络药理学-代谢组学-PK/PD 模型”相结合的分步综合多系统筛选治疗急性肺损伤的中药经典方剂清燥救肺汤的质量标志物。
Phytomedicine. 2020 Nov;78:153313. doi: 10.1016/j.phymed.2020.153313. Epub 2020 Aug 25.
8
Bu-Shen-Ning-Xin decoction ameliorates premature ovarian insufficiency by suppressing oxidative stress through rno_circRNA_012284/rno_miR-760-3p/HBEGF pathway.补肾宁心汤通过 rno_circRNA_012284/rno_miR-760-3p/HBEGF 通路抑制氧化应激改善卵巢早衰。
Phytomedicine. 2024 Oct;133:155920. doi: 10.1016/j.phymed.2024.155920. Epub 2024 Jul 29.
9
Investigation of the Cellular Pharmacological Mechanism and Clinical Evidence of the Multi-Herbal Antiarrhythmic Chinese Medicine Xin Su Ning.多味中药抗心律失常中药新药心速宁的细胞药理机制及临床证据研究
Front Pharmacol. 2020 May 6;11:600. doi: 10.3389/fphar.2020.00600. eCollection 2020.
10
Xin Su Ning-A Review of Basic and Clinical Pharmacology Integrated With Traditional Chinese Medicine Antiarrhythmic Theory.辛苏宁——结合中医抗心律失常理论的基础与临床药理学综述
Front Pharmacol. 2021 Nov 11;12:657484. doi: 10.3389/fphar.2021.657484. eCollection 2021.

本文引用的文献

1
Vericiguat alleviates ventricular remodeling and arrhythmias in mouse models of myocardial infarction via CaMKII signaling.维立西呱通过 CaMKII 信号通路减轻心肌梗死后小鼠的心室重构和心律失常。
Life Sci. 2023 Dec 1;334:122184. doi: 10.1016/j.lfs.2023.122184. Epub 2023 Oct 20.
2
An mTORC1-Dependent Mouse Model for Cardiac Sarcoidosis.mTORC1 依赖性心肌肉状瘤病小鼠模型。
J Am Heart Assoc. 2023 Oct 3;12(19):e030478. doi: 10.1161/JAHA.123.030478. Epub 2023 Sep 26.
3
Dapagliflozin ameliorates sepsis-induced heart injury by inhibiting cardiomyocyte apoptosis and electrical remodeling through the PI3K/Akt pathway.
达格列净通过抑制 PI3K/Akt 通路改善脓毒症诱导的心肌细胞凋亡和电重构,从而减轻心脏损伤。
Eur J Pharmacol. 2023 Sep 15;955:175930. doi: 10.1016/j.ejphar.2023.175930. Epub 2023 Jul 20.
4
Remodeled connexin 43 hemichannels alter cardiac excitability and promote arrhythmias.重构的连接蛋白 43 半通道改变心脏兴奋性并促进心律失常。
J Gen Physiol. 2023 Jul 3;155(7). doi: 10.1085/jgp.202213150. Epub 2023 May 16.
5
Downregulation of cardiac PIASy inhibits Cx43 SUMOylation and ameliorates ventricular arrhythmias in a rat model of myocardial ischemia/reperfusion injury.下调心脏 PIASy 可抑制 Cx43 SUMOylation,改善心肌缺血/再灌注损伤大鼠模型中的室性心律失常。
Chin Med J (Engl). 2023 Jun 5;136(11):1349-1357. doi: 10.1097/CM9.0000000000002618.
6
TRIM21 deficiency protects against atrial inflammation and remodeling post myocardial infarction by attenuating oxidative stress.TRIM21 缺乏通过减轻氧化应激来保护心肌梗死后的心房炎症和重构。
Redox Biol. 2023 Jun;62:102679. doi: 10.1016/j.redox.2023.102679. Epub 2023 Mar 22.
7
Connexin hemichannels as candidate targets for cardioprotective and anti-arrhythmic treatments.缝隙连接半通道作为心脏保护和抗心律失常治疗的候选靶点。
J Clin Invest. 2023 Mar 15;133(6):e168117. doi: 10.1172/JCI168117.
8
Diminished α7 nicotinic acetylcholine receptor (α7nAChR) rescues amyloid-β induced atrial remodeling by oxi-CaMKII/MAPK/AP-1 axis-mediated mitochondrial oxidative stress.α7 型烟碱型乙酰胆碱受体(α7nAChR)减少通过氧化钙调蛋白激酶 II/丝裂原活化蛋白激酶/激活蛋白 1 轴介导线粒体氧化应激减轻淀粉样β诱导的心房重构。
Redox Biol. 2023 Feb;59:102594. doi: 10.1016/j.redox.2022.102594. Epub 2023 Jan 2.
9
The effects of a caffeine containing pre-workout supplement on β-adrenergic and MAPK signaling during resistance exercise.含咖啡因的运动前补充剂对阻力运动期间β-肾上腺素能和丝裂原活化蛋白激酶信号传导的影响。
Eur J Appl Physiol. 2023 Mar;123(3):585-599. doi: 10.1007/s00421-022-05085-0. Epub 2022 Nov 16.
10
Effect of WenXin KeLi on Improvement of Arrhythmia after Myocardial Infarction by Intervening PI3K-AKT-mTOR Autophagy Pathway.稳心颗粒通过干预PI3K-AKT-mTOR自噬通路对改善心肌梗死后心律失常的作用
Evid Based Complement Alternat Med. 2022 Sep 29;2022:2022970. doi: 10.1155/2022/2022970. eCollection 2022.